From GlobeNewswire: 2025-06-05 18:38:00

Xilio Therapeutics, Inc. announced the closing of its underwritten public offering, raising $50.0 million in initial gross proceeds. If all Series B and Series C warrants are exercised in cash, Xilio could receive up to $150.0 million by the end of 2026. New investors Coastlands Capital and Frazier Life Sciences co-led the financing, with participation from Gilead Sciences, Logos Capital, Samsara BioCapital, and other investors. The proceeds will be used to advance the development of Xilio’s product candidates and for general corporate purposes. The offering was made through a shelf registration statement on Form S-3 with the SEC.



Read more at GlobeNewswire: Xilio Therapeutics Announces Closing of $50.0 Million